Case study 01 · Rare disease
44 emerging researchers.
15 countries. 9 funding bodies.
One deliverable.
A pharma BD team needed to understand the global landscape of emerging researchers across 8 rare bone disease sub-types simultaneously — from OI gene therapy in Germany to ACH FGFR3 inhibitors in France to growth plate iPSC models in Japan.
Project scope
8 sub-types. One unified database.
Funding bodies scanned
NIH is just the beginning.
We scan the world.
North America
NIH (NIAMS, NHLBI, NICHD, NIDCR) · OI Foundation Geisman Fellowship · Soft Bones Foundation · FD/MAS Alliance MDBR · Canadian CIHR
Europoe
EU Horizon CHANGE network · ERC Starting/Consolidator · DFG FOR 5567 · ANR/INSERM · Telethon Italy · UKRI/MRC · Brittle Bone Society · ZonMw · FWO Flanders · AEI/Carlos III · EJP RD / ERDERA
Asia-Pacific & Other
JSPS KAKENHI · AMED Rare Disease Program · NHMRC (Australia) · Finnish Academy · Folkhälsan Foundation · Swedish Research Council (VR) · MIUR (Italy)